Interleukin-4 down-regulates MHC class II antigens on cultured rat astrocytes

Mammalian cerebral astrocytes can be brought to express major histocompatibility complex (MHC) class II molecules upon appropriate stimulation. It is well established that this expression is subject to modulation by several neurotransmitters and cytokines. We show that the low, basal expression of M...

Full description

Saved in:
Bibliographic Details
Published inGlia Vol. 17; no. 2; pp. 175 - 179
Main Authors Morga, Eleonora, Heuschling, Paul
Format Journal Article
LanguageEnglish
Published New York John Wiley & Sons, Inc 01.06.1996
Wiley-Liss
Subjects
Online AccessGet full text
ISSN0894-1491
1098-1136
DOI10.1002/(SICI)1098-1136(199606)17:2<175::AID-GLIA9>3.0.CO;2-1

Cover

More Information
Summary:Mammalian cerebral astrocytes can be brought to express major histocompatibility complex (MHC) class II molecules upon appropriate stimulation. It is well established that this expression is subject to modulation by several neurotransmitters and cytokines. We show that the low, basal expression of MHC class II antigens on cultured rat astrocytes is concentration‐dependently down‐regulated by low concentrations of interleukin‐4 (IL‐4), reaching maximal inhibition at 10 U/ml. The higher, γ‐IFN‐induced, expression of class II molecules is also decreased by increasing concentrations of IL‐4, significant effects being already observed at 5 U/ml. Since the cAMP as well as the nitric oxide dependent cGMP pathway have previously been shown to mediate an inhibition on astroglial MHC class II expression, we measured the intra‐cellular content of cyclic nucleotides after stimulation with IL‐4. No rise in cAMP or cGMP is detected. Similarly, IL‐4 does not affect the induced synthesis of nitric oxide radicals. Since MHC class II expression is a critical step in many regulatory processes of the cellular immune reaction, IL‐4, via its activity on astroglial cells, emerges as an important modulator of immunological activities in the central nervous system. © 1996 Wiley‐Liss, Inc.
Bibliography:ark:/67375/WNG-3PX5DDXZ-Z
istex:413E3C275617A76CCC9DF6352D14A2A0430CBD5C
ArticleID:GLIA9
CRP-Santé Luxembourg - No. 92/03
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0894-1491
1098-1136
DOI:10.1002/(SICI)1098-1136(199606)17:2<175::AID-GLIA9>3.0.CO;2-1